BCPC - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to Balchem Corporation's quarterly conference call for First Quarter Financial Results. At this time, all participants are in a listen-only mode [Operator Instructions].

As a reminder, this conference is being recorded. It is now my pleasure to turn the conference over to your host, Mr. Martin Bengtsson, Chief Financial Officer. you. Thank

begin. may You

Martin Bengtsson

name and Ted morning you of to quarter President. call XXXX. for ladies Officer Chief conference hosting our and Balchem joining Chairman, call the this My XX, March this discuss me ending Martin gentlemen. morning, Bengtsson, for Financial is Thank with our Corporation is Harris, Good the and results CEO,

risks This this release counsel, involve differ our Balchem's expectations, or time, of will that contain We statements reflect prove assurance no the correct, our auditors our and factors forward-looking Form including SEC, which read advice and XX-K. will risks statement. would materially I belief that from likely and at could give does identified to the like and various in reflected or events statements, results forward-looking uncertainties. contain expectations to Following the in concerning forward-looking future expectation factors can cause Balchem's

in this Ted their CEO Harris, President. Forward-looking to statements and entirety our call I are cautionary will turn the by qualified Chairman, over now statement.

Ted Harris

ladies net gentlemen. million $X.XX Good $XXX morning, basis. net per which on of conference first reported quarterly and morning $XX.X Martin. And consolidated sales our welcome million, in a GAAP resulted call. income Thanks of This quarter to we share or

share. $X.XX $X.X or quarter compared and million the our earnings transaction quarter compensation non-GAAP of non-GAAP expense, prior the a $X.XX per per equity year earlier release million press decrease of year this of excess to in costs, $X.XX performance These or non-cash tax morning fees million reported comparative facilitate amortization and first operating represent evaluation Our tax prior from $XX.X share $XX.X $X.XX net earnings or million million unallocated share of of or $X.X net per share benefits exclude of with adjusted legal $XX.X per integration versus period.

quarter first operations free flow of XXXX flows of cash the $XX.X We $XX million for quarterly from cash million. with also delivered quarterly

the million continued prior first Products in the Specialty strength quarterly disruptions not $XXX Our the prior weaker expected volumes was saw sales the Industrial related benefits repeating euro, in exchange quarter. & XX record sales this fracking Animal decline of Human growth. the oil by driving The foreign of by impact $X.X net our comparable low sales Health Health Nutrition our year X.X% lower segment segment year. and our to offset Along to from a Nutrition point compared and to decline in and in our to year. due year with a remain prior We than year-over-year segment, Products supply negative gas achieved million driven Chinese impact negative were a where quarter to basis

or of dollars year margin million prior $X.X gross million. consolidated million QX compared Our were $XX.X of with period $XX.X X.X% the same down the in

mix compensation and Our to XX.X% consolidated was primarily and $XX.X to the was as million year. due The million $XX.X certain in operating expenses prior first monogastric expenses. decrease gas XXXX related a oil were the volumes to in lower for and compared in decrease businesses. the quarter the Consolidated European activity principally monogastric sales gross certain increased margin QX from to decrease inefficiencies basis competitive in in market, XX percent of primarily The of was quarter in XXXX. due points the down due XX.X%

expenses intangible or million, with of assets $XX.X Excluding operating were of XX.X% $X.X expense non-cash amortization of operating associated million sales.

SG&A leveraging will our our operating forward continue existing expenses to and tightly Looking on focus infrastructure. controlling we

of state $XX.X share million generated comparable Adjusted earnings $XX.X release earnings $X.X We quarterly $XX.X detailed down diluted for quarterly diluted tax XX.X% $X.XX compensation posted million was share rates million million cash adjusted the as in flow share balance over our $XX.X of year net million prior $X.X first quarter the share our based quarter or XXXX million quarter into earnings our $XX compared year, $X.XX. of year's net and out for at for and down result decrease XXXX down is debt Consolidated year. and net First of last year. the first $X.XX in with release, income basis $XX.X were The net and $XX.X On expense quarter million $X.X below X.X% earnings in million, X.X% XXXX effective EBITDA excess to $XX.X translated earnings an quarter stock from diluted adjusted closed in cash million and and we million. per first from quarter current earnings on XXXX. lower the of or a was quarterly adjusted as of $X.XX prior morning, the the income this $X.X detailed XX.X% prior from were taxes. tax $XX million Interest $XX.X was or were quarter. per the prior quarter tax of $X.XX higher $X.X the GAAP million were compared compared increase with an of million year million million free quarter the in basis, which Company's the rate the from per or closed $XXX first sheet. per primarily respectively. decreased $X.X million attributable to operations to X.X% The million or effective our net benefits as in On the operations

of XXXX and the in working $X of first quarter XXXX. approximately and As call, XXXX cash of expenditure These quarter reverse likely million first timing of to payments flow in the This in $XX.X the expenditures million dividend indicated capital impact XXXX. generation QX XXXX. of strong several quarter expect did noted million now sheet cash items. loan items would the last of expected and on to The as particularly revolving of $XX totaled payment occur capital $XX our normalized the on million, reflects see flow million our through capital of favorable and of was cash fourth remainder the balance we due $X.X

oxide customers to service to basis. transaction on purchase XXXX Balchem's the the back Before addition XX%. by Balchem a held medical results in ability with oxide to gases our more to Asian Grimbergen, geographic sterilization to the basis. in yesterday sterilization would as Martin announced of leader a our update a signed global strategic in the ethylene company specialty leading and accretive be Balchem initiatives. few acquire margin earnings expands are to and Chemogas' that of and approximately privately device supply passing combination a position our is the on our of and headquartered call critical per a be Belgium, global for cover is approximately for you in primarily great existing The we acquisition million. the industry. significantly like of leader of distribution Chemogas activities is million European EURXX EURXX to device packaging This agreement of support adjusted revenues markets. enhance price position two ethylene Late U.S. an presence a detailed the our segment, companies NV, key Chemogas and on I a has share our the XXXX growth definitive to significantly medical to in This to expected will expected to an EBITDA in

the as team This research next and it European and and food functionality Balchem to to some XM around PetShure both American specialists these already superior next products industry milestones at our for the invested ruminant pet as protein stability past value first starting during allows in the being of are same efficient old. our Within unique our the our announce recognized in our leading with study in ruminant This who both proud pregnancy dairy initial North discussed in the a Cornell portfolio The conducted value seven for on Kansas proven novel for nutrition innovation that industry. business childhood. business, Our over space well year ingredient and weeks. convenient superior in study and on Animal event in Petfood offerings course pets innovation seen extensive preservation growing and This These amino and have Nutrition dairy Nutrition see rumen dedicated now cognitive important ability the neurologic to achieved as creating we calls, cognitive study markets on University, platforms. Health the the offers additions pet and in that the for their during control provide Health product the choline at to benefits acid week deliver new launch researchers teams research our persist Cornell required solutions the deliver has several farmers is testing enhanced an essential later commercial to parents. supplementation if launched life methionine. exciting and and Human and internationally previous Forum a have the new feed to and enhanced introduced AminoShure some to manufacturers, choline bioavailability food years newest are expanding In arrival several treat of the protected in and forms; generation into world. is of follow children pH City,

to Gastroenterology Rick Cornell X about learning be other CEO and relative their presented Joan discussed team Joan they met to Fallon the unique University informed pre-submission us the Founder and be from of choline recent clinical meeting. Fallon, We their most regards effects to Administration XXXX. from the study the develop important topics, Society met that as autism, steps XXXX, the completed work that the will to Congress X, U.S. recently with Drug for are year are several at with of for that submission the to pleased Amongst ultimate end Scotland, they as III we Edinburgh, enduring Curemark of and the for an the recently study Hepatology us in a in Food on informed Curemark application With necessary who Nutrition treatment about to for The results from We European was progress forward to the updates making. look olds. approval. well results Curemark's need and the Phase report follow-on taken at Dr. this have by Canfield June

will pleased on later Society clinical to the from III annual certain Pearson the at in today of Texas XXXX Montreal, principal that study, their Research Phase we studies were from findings investigator Phase Canada. Regarding results INSAR Dr. the hear Houston, the International Center, University III presenting or meeting from the the Autism recent Deborah of study, the Science Health be most for

Application to informed the to or instead of for approval, will FDA approval application recent that an submission the need are evolving both file taken Regarding nature of License steps guidance biologics. need or be a in given we BLA provided the Application of Curemark process the NDA of ultimate Drug an by on necessary and the Biologics New for that product

We which contribute the and come would earlier Balchem Joan needs manufacturing broadly with with first to fact to Curemark implications share made. be but encouraged their BLA also Balchem to are both for governance for process. an Balchem. is to am the years that social I work report environmental, update by also positive have approval are its being a working a the specifically report that The that understand this development that consultants ESG released with our development recent We and managing for sustainability project, week which Company's the versus whole Fallon's Curemark this commitment performance. NDA, and or very excited and XX learned captures appreciate one years of exclusivity progress the the five we successful to relative of

have world passionately the this needs past and sustainability innovative report, nutritional while the our While years engaged health our in first is formal all our for XX facilities and operating of developing solutions we businesses the to delivering spent and stakeholders. the of expectations of

of our goals to the place. to the foundation is shares going built ambition turn to vibrant these have This making world go the call a Martin detailed results Company that to back and each contributes healthier now I'm through and commitments meaningfully to stronger objectives. to segments. the be Our we report for a our and over communicates more

Martin Bengtsson

you, Thank Ted.

solution higher to prior sales Health the systems markets X% cereal our by sales. due expense, $X.X increase sales compared from Nutrition quarterly increase sales increased Human with increase and also prior sales million, partially operations and delivered or million X.X% quarter Nutrition quarter, or Human and along driven achieved $XX.X an the by of of lower $X.X $XX.X million, a offset Primarily earnings from Health of to year. was an food first mix. record amortization ingredient For and record primarily The million of year. into higher segment beverage

expense the were were assets from selling million earnings year into increased due of $XX.X effect our the Nutrition million year-over-year feed quarter compared driven lines monogastric animal growth. Excluding prior to increased $XX.X and offset lower in mix. product for partially adjusted average associated by $X.X to operations X.X% impact $X.X in markets of ANH or $XX.X $X.X segment by targeted Animal global $X compared Sales volumes Sales with ruminant intangible of Health negative prior the for from Sales species million, negative prices in or a result competitive compared supply to as to a driving million by decrease of exchange quarter. the year million million, impact year prior acquired the of non-cash due the market of year. year. million of impact Chinese X.X% prior to European this amortization X% species or a million activity The prior for this repeating segment not notable increased benefits is with choline first most foreign to disruptions segment decreased lower X% are our volumes $X.X the from as monogastric

monogastric record As Nutrition earnings calls on to business million the volumes result operations $X and million Specialty benefited oxide and in disruption. device Products operations first medical from in quarter prior achieved $X noted of year of margins $X European as $X.X first was from segment XXXX Health were activity. million million quarter, the sales year primarily Animal compared a of million million. million the down quarter. in from of sterilization the in an $X.X the million market. increase prior of we ethylene QX we've approximately quarter due of QX competitive from for of of increase this year as by earnings The of quarter Products XXXX were and million prior versus $X.X prior $XX.X with increased Specialty temporary X.X% $XX.X higher quarterly $X.X The driven for sales lower

forecast sales non-cash higher associated the million with assets operations derivatives was segment the increase segment year. prior decreased of aforementioned oil downs. sales But the to improved remain or accurately on past Excluding discussed this and primarily quarter in of applications. solutions Basin. back first pick driven hard $X.X market ups million, from due been this intangible the decline million an the come XXXX activity XX.X% gas mix. of and has The the logistical quarter in to choline million million around We we up the effect in expect sales as believe $X.X for by of it were the fracking do the driver amortization in the the to second transportation Basin. In expense line prior compared cautious Permian fracking earnings Permian this $X.X adjusted We primarily used year half historically from of cyclical primary as Products in and $X.X Industrial about of for of to $XX.X is reduced shale business we've choline and and the the slower

am to now Our volumes. to prior turn operations going segment Ted the million, million back some due compared lower were earnings a quarter the decrease I closing remarks. from Products the call of year for with sales $X.X $X.X to over Industrial for

Ted Harris

this continue headwinds net Thanks of Martin. facing of certain albeit down revenue year we X Chinese previously We believe in lower across in time encouraged U.S. the activity with milk our year the should At in of within in The noted turn earnings activity. cautiously while disruptions healthier progresses. environment and but Permian combination will profitability to with last aid down monogastric year monogastric lower fracking component quarter for in in by headwinds and are us recent in and QX, benefits dairy business these first slightly as Basin. the we elimination year-over-year milk of dairy In completion will up the the ramp the shale wane improved provide same feed protein fracking half farm the and second from growth comparative of pipelines as should particularly milk prices. increases picks operate the segments and the delivered the prices solid benefits consolidated costs supply our economic we X saw

our We companies the leader supply two are combination the will device more service creates global very support acquisition and in the the ability The industry, significantly our a excited of of to Chemogas critical global basis. enhance ethylene of medical sterilization oxide customers which to our NV. about on clearly

with initiatives opportunities that and we made on in We in progress the markets. on our growth are believe QX we well-positioned growth pleased the capitalize strategic our are key to XXXX

strengthen We exercising seeking who value opportunities. and Martin? on will open strategies, would call up focusing to back Company Martin questions. hand continue by management our to will creating over the to I our core call the like now acquisition disciplined for cost

Martin Bengtsson

This Ted. we the of this you, up conference the formal questions. the Thank open point, conference. portion now At call will for concludes

Operator

Thank Instructions]. you [Operator

Our with your question. proceed Brett Seaport first Global. comes question from Please Hundley with

Brett Hundley

just a a It bit? of to that far and you business the understand Chemogas. become going does makes I I of is aspect as so North Balchem the a but always to far to to with says we in that as about approach a of have of it my number opinion. in it. enterprise. start you respects global talk curious what completely transaction like signal look moats with Can complete little sense a very on wanted Congratulations of globally number attractive your line agreement. meat that a the thought And in expansion. I'm operations historically, thought area international had outside America, increasingly It's as North when we've or guys coming America, some this business Balchem areas in

Ted Harris

company excited really think really Chemogas, U.S. find the like market this create are opportunity is the synergies. we to what very think markets line point still a for will good be there the have internationally? market, in, the given that a like our Balchem unique that of there of product so I one very are in about we leader to strong XX% your We does the global become around, U.S. this this We don't U.S. We we're good a the But the we're attractive. means in, opportunity in do continue about feel is to still a are it we sales necessarily in growth lot for in increasingly important us we here global is

specifically don't have that. us opportunity without a internationally said to Europe. is growth we growth, could there This very the medical in So good specifically, internationally find have device that not or acquisition go to significant business feel Europe into business that, we expanded for like sterilization but having acquisition we like

know Animal is there significant and as recently in that you Nutrition U.S. but our You We lot know in business expand see penetration Health the a bought also opportunity there, here growth to that needs to Europe. we happen Bioscreen more

provides of businesses two more our Health had Europe have us in was Animal next there's now plants, for up until a to significant third. of potentially business will just us Two and make this And operations operating sterilization Europe. does And more you Europe. headquartered for infrastructure over significant So, business. will for there if Nutrition essentially further It now we'll leverage. step the it a logical we've with little growth have in bit a and in the

opportunity in this a reason global a in in to result the is unique line. feel primary good and a leader us could we more But really for was it build product very market expansion So ultimately Europe. this

Brett Hundley

because try And into Animal, Thanks for that them that. on limit your I'll I'm one you here. one I a of just comments have glad bunch touched on on big that. questions and

expanding Animal internationally. on have you business, your that been So

prepared products comments. new some touched have you in You out your coming that on

here some in Animal business a just that, to if for the I in mentioned, whole as but the growth of ASF. because pig we need relates at need just I that, just But supply I'm wanted what's and the this ruminant? some of about thought Again, that the you've get that of is that Animal really in when think online least I about it and the decimated the now And for what really that I effects the what is year from readjust see temporary I as America. China And your you expectations frankly there. at well Martin and bringing if could because with is for thinking on So, domino what business? a in of how would two your like be I'm there to on comments little mean volume immediate fighting to we noise bit, your products for gastro love forward? moves wanted pig next new think potential frankly, some business, business your the made, on hear over situation. view comparison through has you're herd to a might going look you be is standpoint trying herd to specter North higher And business forward international to I government to your business growth get exclude of filter by the my thinking the expectations right or real area my both on the been pricing growth positive in because I a this some you going

Ted Harris

level us perspective, ability much market given try than lot increase products with consumption our that to the and have protein long to grow the offer Brett, think as faster We but Europe will a penetrate. that the Animal the of very on are market U.S. and capture to If in So markets we bullish allow position grow the world's I term. within I'll it poultry, swine then I further within as our obviously will market continue the position a it Nutrition and in can. look high we and our to from of to that the and dairy there

there are gain impacted quarter the a that or XXXX one will we quarter this impact in So and is so supply from term disruptions lot comparables gone obviously the impact we're bullish, makes some negatives, from some positive. that next short also received of huge really year-over-year difficult. long term Obviously that's away, China, that but

On per close milk the big significant side significantly I near pick hundredweight up $XX the seeing is positive $X Milk a though, are to we here prices year-over-year. up in now there, a prices increase think increase are U.S. year-over-year. protein which which is

little should we we're a how words could think of grow use years. been not And impacted quite to and business growing. I and we're prices at rebounding So couple like rates impact then historically fever cautiously lower throw sure cautiously honestly African at will certainly And tunnel have for able of that than milk around have the the negatively last environment it dairy growing a economic us. in swine there, we and business the that we're the of end the our significantly been light that and encouraged, there by has is ultimately that, be that think on impact of dairy optimistic that bit the you

muted are reports out I compared happening. really what's China think to of the that

We of that grow in but be months, most coming the time, increased I to nine would populations, the Exports that's from reports pigs pig that pigs significant may fed U.S. be base are the the it reveal. think will in culling this and skyrocketing, us months U.S. sow out more populations think the undoubtedly. choline ultimately inventory the at do we'll slaughtering takes months, six of has in of benefit largely been think increased help while XX it a country. than of us, I will this away in that point or will but China even which see

it short think faster result of population. to in that in I the will and the bird pig us term consumption than should is the shortage replenish the increased population help pork and poultry

we're So positive would or that really a is ahead. QX, in opportunity those results it's coming. I but of did in today say our an see None we we think seeing

On tend why are the benefits the choline low to very the sure and side and demand lower than lower historically be is fact right exporting negative attempting choline and in ASF that prices saying, the not for at to of we're started now, of export therefore producers seen. China I maybe have quite more we've by

So we, in China. the elimination Europe demand exacerbated lot further disruptions fact without domestic of of even are, the the been also by Chinese in but the has back, that yes, a supply

today. So I think that's negatively hurting us

long very Nutrition. need get we're closely, us bullish see that the on hurt So, ASF, Chinese really all term watching on it we into that Animal period do market. pretty hasn't negative positive through yet we in it about we're in you talked reentry and this to the But all

Brett Hundley

That's you really species around through world, that's apologize for but making helpful. the go And I really color. helpful each

within trends last the is for to Just talk out one business here, ingredient one get I'll HNH. on I that of wanted about segment. me and solutions

after cost solutions little Particularly comment HNH I solutions not broadly the feel segment you're like strength a new your ingredient you products and areas years innovation seeing talk whether Thank across growth about bit come Your I'm And your in you performance strength you. a and the quarter. from and it about caught my talk eye. and cutting. picking with hearing or of that just for better starting on business up suppliers building your bit more back this business is other ingredient focus players because beverage to to that about just about commentary customers area. was in than expected larger little coincides Can again that food

Ted Harris

was converted growth like a we've, those. about those year. winning the more like reliant it, of beverage was systems if in but Yes, solutions been we the this refocused years, commodity in that generally perspective. bit specialty we feel both from certainly on feel we're we all business really and of quarter the away simply of been Overall, of share do. nutritional perspective partially and bit Drivers there. offers not lot think, our of and growth their SensoryEffects and struggled year for a away a feel our And efforts talked we That and the like as bit we we systems, has we've limited couple the I just disappointing conversions, with won ingredient oils what fair the our indicated a our as of past a of strength and lot business a time We pleased many was and feel of a acquisition some year beverage the business has there. that we flavor bit a really will we in part turned last that really to products. And good beverages, HNH, bottom seasonal we came really, top the We've of with profile we've from part line little from of applications that's corner growth of ingredient a were. came a a of job business, you more business highlight. big the from as food nutritional we This the part line hydrogenated winning applications -- is than a are growth been of all we turned like corner growth from have done very is

us it products the business than we're we companies of very well need fundamentals really up. we and we introduce a good need flavor necessarily some that of these, a like in that's help. formulate. flavors we and have quicker can and We're we positive little not IFF of success offerings. us innovation, a increased that a suppliers systems we we we're or and at buying used to company really do really food where brought we business And we like a And new others. company that in R&D respond and not And the trend We to typically for and do see really any that's to don't good that. because we're so, basic about part coming it important our staff feel need limited-time And saying, companies you

capabilities have more flexibility make manufacturing a smaller products. we plants can bit and that seasonal batch little so Our

it's a we year. And so, of fits is And better feel is that today. think momentum bit have us a quite reason that well. in good we that doing And it I business like that one this trend business

Operator

Ram next proceed Wainwright. question Please Selvaraju comes Our from your question. with H.C. with

Ram Selvaraju

Hi, thanks questions. taking for very much my

was when start through a transaction purchase the confirm that you going Can Chemogas the couple Chemogas So in expected close by is where to cash specifically what and from I please? the acquisition. and dollars aspects is to of wanted coming price for of

Ted Harris

Sure.

Martin Bengtsson

value Ram and for this is Martin. enterprise Sure, acquisition the The million. was EURXX

do $XXX as $XXX That's So do they million, that would your you debt. a there, on call basis, debt translate that you million, quick $XXX million. come some cash it with to math free, free

being financed the So what This door. we're it bit actually revolver. end that little lower terms paying our in dollars in of $XX is the about than a is through than out call U.S. cash in existing lower million that,

We're capacity using have million than a million to less revolver. a lot today. closer that, We $XXX of $XXX currently

out revolver hand. also on take cash existing and of So our our we will this

So speak, if million-ish, you position at so debt to $XXX look million. net at our $XXX current we're

debt million add to that So approximate another will $XXX this position.

debt as X.X today. we're about So at leverage

So closer this position the X.X us. from debt to bring for up a leverage will us

Ram Selvaraju

transaction And when do to you close? expect the

Ted Harris

of bit at an a this is this point. estimate So,

or certainly week for two waiting will within away. just approval be And one country. from the it be expect are that to we hope a more a month. that We And like

as only we're the can. approval we from waiting really pushing thing that as country that's that So is one we're regulatory fast and for

Ram Selvaraju

for competitive bidding this, put this whether for itself in up Chemogas a had if about are Can opportunistic or was sale? you whether fact process you us elucidate

Ted Harris

owned not years Gilde a only a approached private while approached we a situation. Management. owned considering We they firm by Chemogas competitive a -- both was this of So was in transaction and Netherlands called management few them benefits and it saw with Balchem. the Belgium, for had and equity And the

them with to that process exclusive a into was us. went we so, And

Ram Selvaraju

only confirm, on that markets just right. And are European only the to and operate. Those Is they focused in Asian correct? which Chemogas serving is clients

Ted Harris

But and Predominantly East. Central play America. their are did at Europe of the they ship in U.S. in Middle in a sales bit But product all, mass but not the Asia, they play and to some majority they not the little U.S. the South did do in

Ram Selvaraju

disposed... you Okay, and

Martin Bengtsson

of Ram, in I sales their thirds are about Europe. directionally two think

Ram Selvaraju

And likely purchase in what oxide whether the based was fact coming can ethylene disclose was there multiple business? your on you revenue and from that synergies any the are paid existing price to be this given

Ted Harris

today. mean, EURXX million is sit about their as I revenue Yes, here we

revenue. is we're X.X value X, EBITDA XXXX multiple It's multiple an million XX on that on paying. on enterprise about XX So their a that

question a of where second from So your that's was... the we perspective, And Ram sit. multiple part

Ram Selvaraju

Synergies, if or here you not. synergies expect any

Ted Harris

run that also year it's Yeah, we synergies on procurement, have some we modeled in and synergies. $X.X full comes run expect $X.X things. rate a some year about that But And it basis. commercial savings overhead baked comes three million as from from million it in synergy comes a some it's rate about we and from the

Ram Selvaraju

quick autism And then candidate. the questions I just had of a couple regarding

You Are said be at have to be this there you you provide for it presented that us possible to access would is some INSAR to that Phase Meeting. not? III going data presented and or are whatever to to going information

Ted Harris

will answer there the yes, is is I have to will at and that for we results believe of who us. that team reporting INSAR the be today presentation certainly to be back a the

for We have presented that will the be access to abstract meeting. the signed we as up

able and share quite more that's publicly how is the the But do shareholders presented. attending The expectation was with we the see try seeing to results. to certainly interested meeting and from in would you certainly our we're figure out is formally be of abstract that the to our forward we'll So presented presentation in more once we're today But broader to that. that firstly that our brief what today very information perspective. looking positive exactly and to

Ram Selvaraju

available Is this abstract juncture? at the publicly

Ted Harris

I it think is. don't

That's been make do for presented it more check to be how it. available at sure find on people But a INSAR, it that's about public and believe to also for we'll what I INSAR the that XXX% got readily consumption. we will way believe certainly available. it registered broadly access that available And once it's to a was who I think that. I'm not Meeting. just But I

Ram Selvaraju

classified you that for formally be BLA work now the what that additional a manufacturing might And responsible on information as additional filing it's elaborate be filing? of been can subject versus the you or would an NDA

Ted Harris

and this. the just this very help really firm to that specifically we So with have a weeks really haven't. do us We We're just coming set up will learning meeting understand consulting in the trying understand.

around that it's It the molecule BLA outside manufacturing what consistency is manufactured ensuring is high of will I if with you're expect clearly when that on level is parameters. is are specific the of work a parameters my what it very approval, it we just molecules on understood clearly maybe seems I'm biologics. specific like bigger manufacturing that is more the think more a an work perspective, and a specific process, part But lot of operating those or the be. about understanding think again, like as focused because from NDA and happens do our understood and oversimplifying as drug you the not

give XXX degrees, operate think we I'll exactly degrees five we're more So at we say plus degrees If with and just minus plus I degrees. a a degrees, going example a we clearly we need five work while that be say, numbers. going And have XXX to happens minus we're to to or hypothetical will to do need have to five at what show, false done. expect to show

evidence and its day sustainable process produce the same that's that a we day will product out. manufacturing have in stable, So and

work the us BLA, see next and much all call. weeks on month. as information in we'll I'm clear well will better And like for as that So enzyme we do will likely the be much, that coming and you for producer. But sure in have the that there more for be the vetted

Ram Selvaraju

be batch transfer And in you involved some going comparability contract the BLA? as that need tech going any whether confirm the generating the become might of as becomes or if going not it data to that can or or well are manufacturer to be in you commercialized of to you batch and be support product whether fact sole in not other involved manufacturer there's to to are to when

Ted Harris

that's But I think process versus a would looking that us we our portfolio be absolutely Obviously, the BLA to that likely years. producer to pleased a the product protection potentially this batch will will for some we manufacturing Curemark. of and we'd even quickly. BLA exclusive obviously be traditional only producer be look year patent redundancy we batch with forming X comparability a this of positive in have we think with which exclusivity, we're and the is successful the comes very than the the with prospects if will data. the particularly comes XX as And both be the exclusivity product. I of And involved in better do only for the to manufacturer strong and pretty

Ram Selvaraju

on one just then aspect. the And question choline quick

cognitive available, have develop by entities business of are if a wind You choline of working lines be that whether standpoint any to this of started publicly disseminable in might that with data to because believe. human tell up and to that Thank is extent you this infant information information since at being to you specifically from benefits potential demonstrating to folks? interested the had talked forward about going us And the pediatric you. grow new I you aimed Can you that come nutrition what out aspect you from expect going products of information? that interest

Ted Harris

complete. this on thanks. and Ram, have calls we yeah invested the is now in study previous study we Again, mentioned that

interest regimen not think and those this adults. cognitive be really old interested that seen disseminate made really Cornell message a X near be efforts prenatal build there that awareness figure about from We're X broadly to that those around do be communicate been able June broadly point childhood we fixed I some that. And a the around we think try my really past. in be And seven the the to results. to really in to results where persisted And will our cognitive believe fairly be study. needs will So future, were least see more through evidence, one while study next cognitive study the of not will in commonly come first see details included to INSAR, call cognition infants able powerful idea we the benefits results follow-on yes, we'll it's quarter, of the vitamin Scotland. that those at that to have data. is to role important similar has choline the results this is specifically these an that that in results more to about prenatal it will show how area presented that the have where but there here. some also that, being I the once on just of access out And the of benefits vitamins, prenatal in will regimen comments the and And in step this seeing a to and and publication on benefits. be minimally speak out we a presentation would with believe essentially part this years to the And some heightened next choline presentation reports it of the we are in is and around is at played in in at

cognition, the a also older think in adults. to we're in now the do also infants invest adult information discussion come really to to has adults. the discussion how as figure children and the children, but further starting trying out not around able that, to more study to increased And in the and participate harness adult dialog that, this I increasing think strength of in to around But there. only studies and infants around be some that memory, company discussion this We is to how do how in

Ram Selvaraju

the just you Can that didn't researcher. just Cornell of name the me who catch was again? tell I

Ted Harris

Scotland. name I he understand presenting himself from this doing he what Rick the his Canfield. will And Sure, be in led really and is study follow-on

Operator

question. question with and with Company. from your comes Sidoti Please Our proceed next Ramgopal Mitra

Mitra Ramgopal

Just two quick questions.

a of on might us any incremental First, an you can that and Ted incurred if give update wondering I this have been consolidation as the that? result was quarter cost ERP systems

Ted Harris

talk the is to about, strategic live. didn't is I really it on relative and think that a other my update some budget. that, pretty while so in about And quite on implementation, We project. gone we're had update initiative We to important now track in positive we talk things have

in financial was about the new do now first as think that of our the we've the past, all I we talked work milestone. consolidation system in

live going The second live went was from to site. at a learnings start good which test Nebraska individual We had one was sites. that. Lincoln, manufacturing in we a And in November of lot

very close well. stable Defiance stable and was things are more Lincoln Lincoln. to site gone start And has QX is, Defiance, very, second we quickly. site not And completely by costs, to live And we live already X site. stable. that by, was Ohio ramping ramping And test sites been up. we doing relative well and it's year to the so additional And implemented. we'll if going next incremental certainly we're like working first all start and the We very has completely things Lincoln went That be very We well, we site. at minor at being and second between feel of the was far. went say really April again. more that I a our fact gap needed would the And before from there quite learn so there to wanted up time gone to now we'll

Mitra Ramgopal

on generation wondering other feel products if ruminant terms there you highlighted product. pipeline in the quickly just introduction, was in could particular pretty of term? your product terms then of next new I you And are near be meaningful any in

Ted Harris

bioavailability we bring there. product available the what's that as launched Mitra, XM. But exploring both to bring example higher M its we've existing of again, also line about production. broadly product we're we're feel is a generation But theme historical nutrients And next to the products. significantly pleased that may higher with I'm today, with even better dairy working AminoShure excited launch in this upgraded methionine bringing product our benefit cows' ultimately really for really or market new is the new efficacy, would of would are called versions product that products our not and our some to say health could key better dairy for bioavailable AminoShure-M that market. that and excited we're be a we on for standing and the market sold I

feel market starting opportunities. bring feel I about we're good to we really as I these of speak. that to so, And of the some And good pipeline

Operator

is question. with McGeary Asset Our proceed Management. from with next Eagle Matt question your Please

Matt McGeary

give been frac hoping of on my more some business. the have questions us could but Most answered, was detail I you

that's been understanding me space, there help a the Just what's there? exactly you in volatile results driving but play mean, and obviously current where I

Ted Harris

needed. our in fundamentally it's product fracking stabilizer where fluids included a is So, clay choline really and is clay stabilizer

are clay And all clay so, not require commonly stabilization, used. geographies Basin is but quite the where Permian one stabilizers

And for the market say is that's Permian is, so, recent Basin, I you where past, been would our certainly really the to be. primary and want

significantly, that driver at taking ago, we impactor out drilling, are business. they're oil completion negative while wells And but gotten cost the in in up a react were ultimately so of positive prices drivers on And us. pick think fracked. that $XXs bit may weeks we're I and a the that because that a on market of gas believe forth. our has good even to to not picking prices could oil involved to costs tell price, our for up reduce back counts simply market awaits as really side, is bigger ultimately impact just our If pipelines that many these much transporting happens the few necessarily oil costs of so fracking on reducing more prices to be the lower us in are little oil to and primary the then there But today. today low so, of Permian have of story the a And not other a business. what the is this and activity really The out Basin drilled, the the region. don't business And the the we rig saw lower

choline, some just So may it product, be diluting they our here cutting to XXX% do trying see our we instead of to of dilute a and save and there product money. using of

those our correlation with into have seen activity of volume go fracking all factors So over good overall fairly we time. but and play,

Operator

I'd and turn comments. this the At Ladies time, we've call the question-and-answer reached to gentlemen, to of Ted session. for like end the back Harris closing

Ted Harris

in So August early the our thank all you to to progress next to on on today. you forward for look QX results the growth our our joining and update call We strategic initiatives. review call

with Capital at bit the next we at Market the New be Chicago. and in talked June the two BMO in meantime, presenting to as report as, the with non-deal May Farm Curemark July in this well and be as little Midwest. as have at about progress On then the road to findings Markets in should Conference one study. call mid-June we in integration Bank Martin Deutsche Annual York certainly XX. the Chemogas relative on I able Cornell published planned back study we'll X, be as from On shows the just the X Conference the to Baltimore on Industrials Sidoti a will In we in and Global well one or point, then Materials And Seaport late

of that, Thanks. again And than sign see events. you one at hope and for off those you joining. So of to we'll other some thank

Operator

concludes This today's conference.

thank You your And time. we you may participation. disconnect your for lines at this

Martin Bengtsson	Chief Financial Officer
Ted Harris	Chairman and Chief Executive Officer
Brett Hundley	Seaport Global
Raghuram Selvaraju	H.C. Wainwright
Mitra Ramgopal	Sidoti & Company
Matthew McGeary	Eagle Asset Management

Balchem (BCPC) 4 May 192019 Q1 Earnings call transcript